poison pill - Search News

Acelyrin Adopts Poison Pill

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

The Business Journals · 22h

Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to prevent hostile takeovers.

BioSpace · 22h

Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.

MarketWatch · 1d

Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.

Seeking Alpha on MSN · 1d

Acelyrin adopts poison pill as Tang Capital Partners raises stake

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the company stock following an unsolicited acquisition offer.

Fierce Biotech5h

Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

BioSpace6h

Pliant Pops Poison Pill as Concentra Threat Looms

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Endpoints News1d

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Acelyrin Adopts Poison Pill

Trending now

Related topics